<DOC>
	<DOCNO>NCT03086785</DOCNO>
	<brief_summary>The purpose study assess efficacy safety patient receive apatinib single combine capecitabine treatment patient metastatic her-2 negative breast cancer .</brief_summary>
	<brief_title>Prospective , Multicenter , Observational Study Apatinib Single Combined Capecitabine Treatment Patients With Metastatic Her-2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>18 70 year old ( female ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Pathologically diagnose her2 negative , ER/PR negative , ER/PR positive failure endocrine treatment , three chemotherapy regimen ( must include anthracyclinebased yew class ) , final failure chemotherapy regimens patient advance breast cancer ; Note : treatment failure include ( 1 ) completion six month less disease progress neoadjuvant adjuvant therapy ; ( 2 ) rescue treatment progress within 3 month less Patients least one measurable lesion advance breast cancer， measurable lesion receive radiotherapy treatment , unless progress treatment ( measuring≥10mm spiral CT scan , satisfy criterion RECIST1.1 WHO ) ; Major organ function meet follow certeria : 1 . For result blood routine test ( without blood transfusion within 14 day ) 1 . HB≥100g/L ; 2 . ANC≥1.5×109/L ; 3 . PLT≥75×109/L ; 2 . For result blood biochemical test： 1 . TBIL &lt; 1.5ULN； 2 . ALTand AST &lt; 2.5ULN , but5 &lt; ULN transferanse elevation due liver metastases； 3 . Serum creatinine ≤1.25ULN , calculate creatinine clearance＞45 ml/min ( per CockcroftGault formula ) ; 6.Participants willing join study , write informed consent . 1 . The patient failure capecitabine treatment； 2 . The patient chest wall invasion , chest wall large canker tendency transfer； 3 . Have high blood pressure antihypertensive drug treatment control ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) , classⅡand coronary heart disease , unable control arrhythmia ( include QTc lengthen woman &gt; 470 m ) classⅢⅣcardiac insufficiency ; Left ventricular ejection fraction ( LVEF ) &lt; 50 % ； 4 . A variety factor influence oral drug ( unable swallow , resection gastrointestinal , chronic diarrhea intestinal obstruction , etc . ) ； 5 . Has history bleeding , clinical significance bleeding symptom , patient definite bleeding tendency , gastrointestinal bleeding , bleed ulcer , baseline period （+ +）and defecate occult blood , vasculitis , etc； 6 . Received major surgery within 4 week severe traumatic injury , fracture , poor heal wound； 7 . Allergic apatinib supplementary material； 8 . Patients active brain metastasis ; 9 . Patients pregnant planning pregnancy ; 10 . The researcher think inappropriate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>